Myelodysplastic syndrome presenting as third malignancy after non-Hodgkin's lymphoma and osteosarcoma.
The patient was initially diagnosed as having non-Hodgkin's lymphoma and was cured following treatment with prednisolone, vincristine, daunorubicin, 1-asparaginase, and cyclophosphamide. Seven years and two months later, he developed osteosarcoma in his right femur. He received chemotherapy consisting of methotrexate, carboplatin, etoposide, and ifosfamide and again obtained remission. After 2 years and 7 months, however, he was found to have pancytopenia with morphological abnormalities in the erythroid and myeloid series. Diagnosis of myelodysplastic syndrome (MDS) was made. Cytogenetic analysis of bone marrow cells revealed -5 and -7, which is typical for secondary MDS. This is a rare case of third malignancy presumably caused by alkylating agents.
Kubota
M
M
Department of Pediatrics, Kyoto University, Japan.
Sawada
M
M
Watanabe
K
K
Koishi
S
S
Kataoka
A
A
Usami
I
I
Lin
Y W
YW
Okuda
A
A
Akiyama
Y
Y
Furusho
K
K
D000293:Adolescent; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects; D002869:Chromosome Aberrations / Q000209:etiology; D025063:Chromosome Disorders; D002895:Chromosomes, Human, Pair 5; D002897:Chromosomes, Human, Pair 7; D006801:Humans; D007621:Karyotyping; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis*; D008297:Male; D009190:Myelodysplastic Syndromes / Q000139:chemically induced / Q000175:diagnosis* / Q000235:genetics; D012516:Osteosarcoma / Q000175:diagnosis*
D018906:Antineoplastic Agents, Alkylating